Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

SUPN | Supernus Pharmaceuticals Inc

Healthcare | Drug Manufacturers - Specialty & Generic | USA | NASD

Index	RUT	P/E	40.08	EPS (ttm)	0.71	Insider Own	4.15%	Shs Outstand	53.26M	Perf Week	0.88%
Market Cap	1.56B	Forward P/E	14.67	EPS next Y	1.95	Insider Trans	-0.58%	Shs Float	52.33M	Perf Month	-9.79%
Income	43.35M	PEG	1.65	EPS next Q	0.04	Inst Own	105.79%	Short Float / Ratio	7.92% / 8.47	Perf Quarter	-6.02%
Sales	634.01M	P/S	2.46	EPS this Y	66.99%	Inst Trans	1.19%	Short Interest	4.15M	Perf Half Y	-20.16%
Book/sh	16.96	P/B	1.68	EPS next Y	12.09%	ROA	2.90%	Target Price	40.25	Perf Year	-13.30%
Cash/sh	2.78	P/C	10.28	EPS next 5Y	24.33%	ROE	4.92%	52W Range	27.26 - 42.09	Perf YTD	-19.93%
Dividend	-	P/FCF	21.93	EPS past 5Y	-0.71%	ROI	4.54%	52W High	-32.15%	Beta	1.05
Dividend %	-	Quick Ratio	1.32	Sales past 5Y	18.07%	Gross Margin	71.95%	52W Low	4.77%	ATR	0.97
Employees	612	Current Ratio	1.68	Sales Q/Q	-20.28%	Oper. Margin	2.78%	RSI (14)	40.18	Volatility	2.48% 3.30%
Optionable	Yes	Debt/Eq	0.05	EPS Q/Q	-	Profit Margin	6.84%	Rel Volume	0.48	Prev Close	28.17
Shortable	Yes	LT Debt/Eq	0.04	Earnings	Aug 08 AMC	Payout	0.00%	Avg Volume	489.44K	Price	28.56
Recom	1.50	SMA20	-5.44%	SMA50	-7.02%	SMA200	-18.17%	Volume	235,808	Change	1.38%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-23	Resumed	Jefferies	Buy	$44 → $45
Dec-01-21	Resumed	Jefferies	Buy	$40 → $44
Apr-13-21	Upgrade	Jefferies	Hold → Buy	$25 → $40
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight	$25 → $31
Jun-15-20	Resumed	Jefferies	Hold	$24
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold	$55 → $23
Nov-06-19	Downgrade	Jefferies	Buy → Hold	$46 → $23
Nov-12-18	Reiterated	B. Riley FBR	Buy	$68 → $65
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy	$54
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy	$50 → $54
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy	$47
Oct-19-17	Initiated	FBR & Co.	Buy	$53
Sep-19-17	Downgrade	Stifel	Buy → Hold	$47
Jul-17-17	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-14-17	Initiated	Janney	Neutral
Jun-01-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-16	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-18-16	Downgrade	Northland Capital	Outperform → Market Perform

Show Previous Ratings

Sep-09-23 08:00PM	Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms (GlobeNewswire)
Aug-31-23 05:30PM	Supernus to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-21-23 09:00AM	Bethany L. Sensenig Joins Supernus Board of Directors (GlobeNewswire)
Aug-08-23 08:30PM	Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics (Zacks)
07:55PM	Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:40PM	Loading…
06:40PM	Supernus: Q2 Earnings Snapshot (AP Finance)
04:17PM	Supernus Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-25-23 06:36AM	Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals? (Simply Wall St.)
Jul-24-23 04:05PM	Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023 (GlobeNewswire)
Jun-27-23 11:50AM	The five-year shareholder returns and company earnings persist lower as Supernus Pharmaceuticals (NASDAQ:SUPN) stock falls a further 9.4% in past week (Simply Wall St.)
Jun-21-23 08:00PM	SUPN: What does Argus have to say about SUPN? (Argus Research)
Jun-10-23 07:40AM	Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy (Motley Fool)
May-31-23 04:15PM	Supernus to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 08:39AM	Top Healthcare Stocks for May 2023 (Investopedia)
11:23AM	Loading…
May-10-23 11:23AM	Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-09-23 08:30PM	Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:05PM	Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates (Zacks)
06:09PM	Supernus: Q1 Earnings Snapshot (AP Finance)
04:05PM	Supernus Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-02-23 04:05PM	Supernus to Present at the Bank of America 2023 Health Care Conference (GlobeNewswire)
Apr-26-23 08:00PM	SUPN: What does Argus have to say about SUPN? (Argus Research)
Apr-25-23 04:15PM	Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023 (GlobeNewswire)
Apr-03-23 04:05PM	Supernus Announces Repayment of Convertible Notes (GlobeNewswire)
Mar-31-23 12:41PM	Top Small-Cap Stocks for April 2023 (Investopedia)
Mar-30-23 05:22PM	Top Healthcare Stocks for April 2023 (Investopedia)
Mar-08-23 04:05PM	Supernus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-02-23 08:29PM	Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 04:55PM	Supernus to Present at the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
05:50AM	Q4 2022 Supernus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
05:25PM	Loading…
Feb-28-23 05:25PM	Supernus Pharmaceuticals (SUPN) Q4 Earnings and Revenues Lag Estimates (Zacks)
04:05PM	Supernus Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-21-23 10:00AM	Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-14-23 04:30PM	Supernus Enters Into $150 Million Credit Facility (GlobeNewswire)
09:27AM	Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? (Simply Wall St.)
Feb-09-23 06:15PM	Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023 (GlobeNewswire)
Jan-18-23 08:11AM	Supernus Pharmaceuticals (NASDAQ:SUPN) investors are up 3.6% in the past week, but earnings have declined over the last three years (Simply Wall St.)
Jan-03-23 07:11AM	Heres Why Supernus Pharmaceuticals (SUPN) Outperformed in Q3 (Insider Monkey) +5.05%
Dec-30-22 12:46AM	Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-01-22 02:37PM	Supernus Pharma's Charts Are Looking Super (TheStreet.com)
Nov-22-22 05:00PM	Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-11-22 05:52AM	Supernus Pharmaceuticals Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-08-22 07:25PM	Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates (Zacks)
05:30PM	Supernus to Present at Two November Healthcare Conferences (GlobeNewswire)
04:05PM	Supernus Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-25-22 04:30PM	Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022 (GlobeNewswire)
Oct-10-22 08:30AM	Supernus Provides Regulatory Update on SPN-830 (GlobeNewswire)
Sep-07-22 09:03AM	Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? (Simply Wall St.)
Aug-31-22 04:00PM	Supernus to Present at the 2022 Wells Fargo Healthcare Conference (GlobeNewswire)
08:55AM	Supernus Pharmaceuticals Appears Ready for an Upside Breakout (TheStreet.com)
Aug-11-22 08:59AM	The past five years for Supernus Pharmaceuticals (NASDAQ:SUPN) investors has not been profitable (Simply Wall St.)
Aug-08-22 10:00AM	Best Momentum Stocks to Buy for August 8th (Zacks)
Aug-04-22 05:25PM	Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates (Zacks)
04:01PM	Supernus Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-25-22 05:00PM	Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022 (GlobeNewswire)
Jul-11-22 11:45AM	2 Small-Cap Stocks With Large-Cap Potential (Motley Fool)
Jun-02-22 04:05PM	Supernus to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-09-22 04:05PM	Supernus Announces First Quarter 2022 Financial Results (GlobeNewswire)
May-02-22 04:55PM	Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022 (GlobeNewswire)
03:08PM	This MoCo biotechs ADHD drug just earned FDA approval this time, for adults (American City Business Journals)
08:30AM	Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults (PR Newswire)
Apr-29-22 08:00PM	Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults (GlobeNewswire)
Apr-13-22 04:11PM	Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Apr-07-22 03:18PM	Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92 (Investor's Business Daily)
Apr-04-22 05:00PM	Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance (GlobeNewswire)
Mar-17-22 08:30AM	Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance (GlobeNewswire)
Mar-02-22 08:00AM	Supernus to Participate in Annual Cowen Health Care Conference (GlobeNewswire)
Feb-28-22 04:05PM	Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-22-22 04:30PM	Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022 (GlobeNewswire)
04:30PM	Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer (GlobeNewswire)
08:00AM	Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA (GlobeNewswire)
Feb-21-22 02:53AM	Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Feb-17-22 03:02PM	Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-09-22 12:10PM	Why the Earnings Surprise Streak Could Continue for Supernus (SUPN) (Zacks)
Feb-04-22 09:38AM	Lisanti Capital Growth, LLC Buys Saia Inc, Knight-Swift Transportation Holdings Inc, ... (GuruFocus.com)
Jan-24-22 01:11PM	Supernus Pharmaceuticals (NASDAQ:SUPN) investors are sitting on a loss of 18% if they invested three years ago (Simply Wall St.)
Jan-18-22 01:38PM	HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ... (GuruFocus.com)
Dec-27-21 11:38PM	Advisors' Inner Circle Fund III Buys Washington Federal Inc, Supernus Pharmaceuticals Inc, ... (GuruFocus.com)
Dec-08-21 06:38PM	Inv Corp Small Cap Value Buys Zuora Inc, Home BancShares Inc, Tegna Inc, Sells Zurn Water ... (GuruFocus.com)
08:48AM	Analysts Just Published A Bright New Outlook For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) (Simply Wall St.)
08:30AM	Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device (GlobeNewswire)
Dec-07-21 11:38AM	Fuller & Thaler Behavioral Small Cap Equity Buys Exelixis Inc, ExlService Holdings Inc, LHC ... (GuruFocus.com)
Nov-24-21 06:58PM	Supernus Pharmaceuticals Targeted in Ransomware Incident (GlobeNewswire)
09:12AM	Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals (GlobeNewswire)
08:25AM	We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt (Simply Wall St.)
Nov-23-21 08:00AM	Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer (GlobeNewswire)
Nov-18-21 08:00AM	Supernus to Participate in Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-21 04:05PM	Supernus to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Nov-04-21 12:01AM	Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call Transcript (Motley Fool) +5.09%
Nov-03-21 05:55PM	Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Supernus Announces Third Quarter 2021 Financial Results (GlobeNewswire)
Nov-02-21 06:30PM	ADAMAS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS (PR Newswire)
Nov-01-21 11:09AM	East Bay drug maker's potential sale brings lawsuits, job cuts (American City Business Journals)
Oct-27-21 05:42PM	Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021 (GlobeNewswire)
12:36PM	ADAMAS ALERT: Bragar Eagel & Squire, P.C. Announces Commencement of Tender Offer and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-26-21 03:02PM	Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-25-21 05:59PM	For a few dollars more: Behind the half-billion-dollar deal for an East Bay Parkinson's Disease drug company (American City Business Journals)
Oct-21-21 07:03AM	Why Supernus' Acquisition of Adamas Is a Smart Move (Motley Fool)
Oct-20-21 08:00AM	Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month (GlobeNewswire)
Oct-19-21 02:24PM	Is Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? (Simply Wall St.)

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khattar Jack A.	President, CEO	Sep 07	Option Exercise	0.00	35,000	0	884,267	Sep 07 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Sep 07	Option Exercise	0.00	2,500	0	8,347	Sep 07 05:00 PM
Martin Tami Tillotson	Sr. V.P., Regulatory Affairs	Aug 30	Option Exercise	23.99	8,100	194,319	93,349	Sep 01 05:00 PM
Martin Tami Tillotson	Sr. V.P., Regulatory Affairs	Aug 30	Sale	32.00	8,100	259,200	85,249	Sep 01 05:00 PM
Martin Tami Tillotson	Sr. V.P., Regulatory Affairs	Aug 25	Sale	31.59	5,135	162,215	85,249	Aug 29 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	May 11	Option Exercise	0.00	750	0	5,497	May 12 05:00 PM
Khattar Jack A.	President, CEO	May 11	Option Exercise	0.00	31,250	0	864,272	May 12 05:00 PM
DEC TIMOTHY C	Senior Vice-President & CFO	May 11	Option Exercise	0.00	1,500	0	3,359	May 12 05:00 PM
Khattar Jack A.	President, CEO	Mar 14	Option Exercise	0.00	20,000	0	833,022	Apr 10 05:00 PM
DEC TIMOTHY C	Senior Vice-President & CFO	Mar 14	Option Exercise	0.00	1,500	0	2,841	Apr 10 05:00 PM
Mottola Frank	Sr VP, Quality, GMP Oper. & IT	Mar 14	Sale	35.99	4,780	172,023	4,737	Mar 16 05:00 PM
Martin Tami Tillotson	Sr. V.P., Regulatory Affairs	Feb 16	Option Exercise	0.00	1,500	0	88,720	Feb 21 05:01 PM
Rubin Jonathan	SVP, Chief Medical Officer	Feb 16	Option Exercise	0.00	1,500	0	1,500	Feb 21 05:01 PM
Mottola Frank	SVP, Quality, GMP, Ops, IT	Feb 16	Option Exercise	0.00	1,500	0	8,944	Feb 21 05:35 PM
Khattar Jack A.	President, CEO	Feb 03	Option Exercise	9.56	330	3,155	804,472	Feb 06 05:01 PM
Khattar Jack A.	President, CEO	Feb 02	Option Exercise	9.56	22,515	215,243	817,674	Feb 06 05:01 PM
Khattar Jack A.	President, CEO	Feb 02	Sale	42.05	13,532	569,088	804,142	Feb 06 05:01 PM
Khattar Jack A.	President, CEO	Feb 01	Option Exercise	9.56	498	4,761	795,459	Feb 03 05:00 PM
Khattar Jack A.	President, CEO	Feb 01	Sale	42.01	300	12,602	795,159	Feb 03 05:00 PM
Khattar Jack A.	President, CEO	Jan 31	Option Exercise	9.56	1,620	15,487	795,937	Feb 02 05:00 PM
Khattar Jack A.	President, CEO	Jan 31	Sale	42.01	976	41,002	794,961	Feb 02 05:00 PM
Khattar Jack A.	President, CEO	Jan 18	Option Exercise	9.56	8,080	77,245	799,253	Jan 20 05:00 PM
Khattar Jack A.	President, CEO	Jan 18	Sale	40.40	4,936	199,394	794,317	Jan 20 05:00 PM
Khattar Jack A.	President, CEO	Jan 17	Option Exercise	9.56	41,920	400,755	816,619	Jan 19 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Jan 17	Option Exercise	9.13	4,826	44,061	6,470	Jan 19 05:00 PM
Khattar Jack A.	President, CEO	Jan 17	Sale	40.03	25,446	1,018,728	791,173	Jan 19 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Jan 17	Sale	39.92	4,826	192,638	1,644	Jan 19 05:00 PM
Hudson Frederick M.	Director	Jan 10	Option Exercise	7.90	8,722	68,904	30,985	Jan 12 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Jan 06	Option Exercise	9.13	174	1,589	1,818	Jan 09 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Jan 06	Sale	39.90	174	6,943	1,644	Jan 09 05:00 PM
NEWHALL CHARLES W III	Director	Dec 28	Option Exercise	7.90	8,722	68,904	110,453	Dec 30 05:01 PM
Khattar Jack A.	President, CEO	Dec 21	Option Exercise	9.56	18,472	176,592	826,053	Dec 22 05:00 PM
Khattar Jack A.	President, CEO	Dec 21	Sale	38.14	11,354	433,070	814,699	Dec 22 05:00 PM
Khattar Jack A.	President, CEO	Dec 20	Option Exercise	9.56	6,528	62,408	795,962	Dec 22 05:00 PM
Khattar Jack A.	President, CEO	Dec 20	Sale	38.02	4,006	152,317	791,956	Dec 22 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Dec 01	Option Exercise	9.13	5,000	45,650	6,644	Dec 02 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Dec 01	Sale	37.48	5,000	187,416	1,644	Dec 02 05:00 PM
Khattar Jack A.	President, CEO	Nov 25	Option Exercise	9.56	17,794	170,111	800,569	Nov 28 05:02 PM
Khattar Jack A.	President, CEO	Nov 25	Sale	35.18	11,135	391,685	789,434	Nov 28 05:02 PM
Khattar Jack A.	President, CEO	Nov 23	Option Exercise	9.56	3,616	34,569	785,034	Nov 28 05:02 PM
Khattar Jack A.	President, CEO	Nov 23	Sale	35.05	2,259	79,189	782,775	Nov 28 05:02 PM
Khattar Jack A.	President, CEO	Nov 22	Option Exercise	9.56	959	9,168	782,018	Nov 23 05:00 PM
Khattar Jack A.	President, CEO	Nov 22	Sale	35.00	600	21,001	781,418	Nov 23 05:00 PM
Khattar Jack A.	President, CEO	Nov 21	Option Exercise	9.56	848	8,107	781,590	Nov 22 05:00 PM
Khattar Jack A.	President, CEO	Nov 21	Sale	35.01	531	18,592	781,059	Nov 22 05:00 PM
Khattar Jack A.	President, CEO	Nov 15	Option Exercise	9.56	1,783	17,045	781,857	Nov 17 05:00 PM
Khattar Jack A.	President, CEO	Nov 15	Sale	35.00	1,115	39,028	780,742	Nov 17 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Nov 11	Option Exercise	9.24	6,800	62,832	8,444	Nov 15 05:01 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Nov 11	Sale	34.95	6,800	237,655	1,644	Nov 15 05:01 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Nov 09	Option Exercise	9.24	700	6,468	2,344	Nov 14 05:00 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Nov 09	Sale	34.97	700	24,480	1,644	Nov 14 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SUPN | Supernus Pharmaceuticals Inc

Upgrade your FINVIZ experience